Skip to content
Trial protocolGut health

BPC-157 80 mg enema, the Croatian ulcerative colitis study

Written by

Calm mild to moderate ulcerative colitis, a bowel disease

The schedule a registered study in people actually used, taken from the paper and the study's public registration, not from a label summary. Every one links a PubMed or ClinicalTrials record you can open.

Not advice. This is a record of a schedule, not a dose for you.

The schedule, as reported

Each field below is what the source states, not a rounded version of it. Where the source does not publish a detail, the field says so instead of filling the gap.

Amount
80 mg
How often
Once daily
How it is taken
Enema (liquid put into the rectum)
How long
Two weeks

What was measured

The change in a standard colitis symptom score over two weeks. Nothing about tendon, ligament, joint or muscle healing was measured, because this was a bowel study.

What was reported

Results as the study reported them, with what they were compared against.

  • 53 adults with mild to moderate ulcerative colitis took part, and 46 finished.

  • On average the symptom score dropped 3.2 points on BPC-157 and 1.6 points on the dummy enema.

  • The gap between the groups was 1.6 points, small enough that it could be chance. In plain terms: people on the dummy enema did about as well.

  • Three people on BPC-157 and two on the dummy enema dropped out because of problems, mostly colitis getting worse.

Where this comes from

Ruenzi et al. 2005, a study at several sites run by Pliva in Croatia under the code PL 14736. It was only reported as a short conference summary, and it is listed in the FDA's review of BPC-157 raw drug material dated 11 May 2026.

This is the only study of BPC-157 in people that compared it with a dummy treatment. It was never published as a full paper, so the numbers above come from the FDA's own notes on the conference summary. The PubMed record below is a 2012 review from the Zagreb group that created the peptide. It confirms PL 14736 reached a mid-stage study for bowel disease and went no further.

What this protocol cannot tell you

Required on every entry in this registry, and never empty.

In the one study of BPC-157 in people that used a dummy treatment, people on the dummy did about as well. It tested an 80 mg enema for ulcerative colitis. That is not the way it is given, the dose, the problem or the length of use of anyone buying BPC-157 for a tendon. It was never published in full, so what is here is an FDA reviewer's account of a conference summary, not a report anyone can read. No study has ever given BPC-157 as a shot under the skin for an injury and reported a result. The first one, a 120 person mid-stage study in hamstring strain, began signing people up in February 2026 and expects its main results in February 2027.

The compounds in this protocol

Each profile has the full evidence record, the legal status and what the studies did not show.

  • BPC-157Limited. People have taken it in a published study, but fewer than 100 of them. 3 completed trials, 31 people given it.10 reported

    A lab-made piece of a stomach protein. It has lots of animal studies on tendon, muscle and gut healing. In people there is very little: two enema studies in Croatia, three small clinic reports with nobody to compare against, and one injury study with a dummy group that is still signing people up.

Other trial protocols in the registry

All protocols